Bristol Myers Squibb (BMY) announced on Thursday that it will sell its moderate-to-severe plaque psoriasis drug, Sotyktu, at a discount of more than 80% to the current list price, starting in January ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback